Amlodipine and Cardiovascular outcomes in Hypertensive patients: What Meta-analysis says
A major risk factor for cardiovascular disease is hypertension. A multitude of drugs, including calcium channel blockers (CCBs), β-blockers, angiotensin receptor blockers (ARBs), Angiotensin-converting enzyme inhibitors (ACEIs) as well as Diuretics have been used as monotherapy or in combination to treat hypertension (1). Initially used for coronary heart disease (CHD), CCBs over the past few years has gained wide recognition for their efficacy in the treatment of hypertension (HTN). CCBs are also being used for angina, peripheral vascular disease, and certain arrhythmic conditions apart from Hypertension (2).
Amlodipine can be safely used in high-risk cardiac patients and is associated with benefits for all major cardiovascular endpoints and total mortality.
Amlodipine-based regimens reduced the risk of total cardiovascular events and mortality compared with non-calcium channel blocker antihypertensive therapies.
They further added that Amlodipine had a protective effect against myocardial infarction and stroke.
Amlodipine can be safely used in high-risk cardiac patients and is associated with benefits for all major cardiovascular endpoints as well as total mortality.
- Minimizing the confounding effect of variability of treatment due to the substantial difference between DHPs and non-DHP CCBs.
- The study was limited to data from actively controlled trials to minimize the effect of blood pressure reductions observed in placebo-controlled trials.
- Only trials that evaluated long term outcomes and having clearly defined primary and secondary endpoints were enrolled.